Placebo News and Research

RSS

MDMA-assisted therapy reduces PTSD symptoms dramatically

New study shows MDMA-assisted therapy significantly reduces symptoms in individuals with moderate to severe PTSD, outperforming traditional therapy and medications. The study, covering multiple sites in the U.S. and Israel, indicates that while effective, further research is needed to explore potential side effects and effectiveness across diverse groups.

17 Sep 2023

Phase 3 study: The efficacy of monovalent SARS-CoV-2 vaccine with AS03 adjuvant in adults

The effectiveness of a novel monovalent recombinant protein vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2023

Results from a nested randomized controlled trial for BCG vaccination against recurrent herpes labialis

Researchers examined the effect of Bacillus Calmette-Guérin (BCG) vaccination on attenuating herpes labialis (cold sore) recurrences.

14 Sep 2023

Idrevadiloride in hypertonic saline improves lung function in people with primary ciliary dyskinesia, trial shows

Primary ciliary dyskenisia (PCD) is a rare genetic disease that causes the tiny hair-like filtration structures in the respiratory tract to stop working.

12 Sep 2023

Herring roe oil's potential in psoriasis treatment

Researchers investigated the use of herring row oil to treat psoriasis, a non-communicable skin disease.

12 Sep 2023

Effective treatment for lower urinary tract symptoms linked to lower mortality risk in older men

Effective treatment for lower urinary tract symptoms (LUTS) in men aged 50 or older is associated with a lower risk of death over the next few years reports a study in the October issue of The Journal of Urology, an Official Journal of the American Urological Association.

11 Sep 2023

Buck Institute receives $3.5 million federal grant to lead clinical trial of ketone intervention in older adults

The Buck Institute for Research on Aging has received a $3.5 million federal grant to lead the first-ever double-blind, randomized, placebo-controlled clinical trial to understand the effects of ketone ester supplementation on frailty, a condition of vulnerability which develops following age-related decline in multiple physiological systems.

11 Sep 2023

Durvalumab shows tolerable surgical safety profile in patients with resectable NSCLC

Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.

11 Sep 2023

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

September 7th, 2023, the University of Birmingham and Acticor Biotech announce the full regulatory approval of LIBERATE clinical study.

9 Sep 2023

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Alzheimer's disease is the most common cause of dementia that affects more than 6.5 million Americans, according to the Alzheimer's Association.

8 Sep 2023

Flash therapy may offer a practical option to delay the circadian clock in shift workers and jet travelers

Researchers examined whether flash therapy, given during sleep, changed the sleep architecture to shift the human circadian clock.

6 Sep 2023

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

The safety, timing, magnitude, and durability of the antidepressant psilocybin on patients with major depressive disorders.

4 Sep 2023

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

From AMGEN 1 Sep 2023

The efficacy and safety of anti-androgens in the management of hormonal and clinical features of PCOS

The safety and efficacy of anti-androgens in managing polycystic ovary syndrome (PCOS).

1 Sep 2023

Low-dose aspirin linked to 15% lower risk of type 2 diabetes in older adults

New research to be presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 October) shows that use of low dose (100mg daily) aspirin among older adults aged 65 years and older is associated with a 15% lower risk of developing type 2 diabetes.

31 Aug 2023

Scientists delve deeper into how vaccines work against leishmaniasis

Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning is in motion for the most promising candidate.

31 Aug 2023

Electrical noise stimulation boosts math skills in individuals with lower brain excitability

Exciting a brain region using electrical noise stimulation can help improve mathematical learning in those who struggle with the subject, according to a new study from the Universities of Surrey and Oxford, Loughborough University, and Radboud University in The Netherlands.

31 Aug 2023

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction.

31 Aug 2023

Impact of vaping high CBD/low THC products on driving ability

Researchers assess how cannabinoid levels in the blood affect driving after single or repetitive vaporization of cannabis rich in CBD.

31 Aug 2023

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.

30 Aug 2023

Placebo News and Research

MDMA-assisted therapy reduces PTSD symptoms dramatically

Phase 3 study: The efficacy of monovalent SARS-CoV-2 vaccine with AS03 adjuvant in adults

Results from a nested randomized controlled trial for BCG vaccination against recurrent herpes labialis

Idrevadiloride in hypertonic saline improves lung function in people with primary ciliary dyskinesia, trial shows

Herring roe oil's potential in psoriasis treatment

Effective treatment for lower urinary tract symptoms linked to lower mortality risk in older men

Buck Institute receives $3.5 million federal grant to lead clinical trial of ketone intervention in older adults

Durvalumab shows tolerable surgical safety profile in patients with resectable NSCLC

University of Birmingham and Acticor Biotech announce MHRA approval of LIBERATE clinical study

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Flash therapy may offer a practical option to delay the circadian clock in shift workers and jet travelers

What are the efficacy and safety of psilocybin in patients with major depressive disorder?

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

The efficacy and safety of anti-androgens in the management of hormonal and clinical features of PCOS

Low-dose aspirin linked to 15% lower risk of type 2 diabetes in older adults

Scientists delve deeper into how vaccines work against leishmaniasis

Electrical noise stimulation boosts math skills in individuals with lower brain excitability

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Impact of vaping high CBD/low THC products on driving ability

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News